Biotech

Ahead of the Curve

Jun 30 2017

Biotech – Cowen Analysis: When Insiders Buy, Investors Should Too

Cowen analyzed 4K+ open market transactions made by insiders at the 10 largest biotechnology companies over the last 10 years. We find that purchases by insiders are a strong predictor of outperformance, while stock sales by insiders have little predictive value. When insiders purchase shares of fundamentally strong companies, a successful strategy would seem to be to buy right along with them.